A monoclonal antibody
Pregnancy category AU: B1
Routes of administration-Subcutaneous injection
Bioavailability 82%
Metabolism Proteolysis
Elimination half-life 28 days
The first CGRPR antagonist to be approved by the U.S. Food and Drug Administration.
Erenumab is indicated for the prevention of migraine in adults.
Side effects: constipation, pruritus, muscle spasms, as well as mild and mostly transient reactions at the injection site.
Erenumab is a fully human monoclonal antibody blocking the calcitonin gene-related peptide receptor (CGRPR).
The medication significantly reduced the number of migraine days per month by 3.2 in the 70-mg group and 3.7 in the 140-mg group, versus 1.8 in the placebo (0-mg) group.